SMMT stock forecast, quote, news & analysis
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases... Show more
Why Is Summit Therapeutics Inc. (SMMT) Stock Down -27.83% Today?
Key Takeaways
- SMMT shares plunged 27.83% to $15.49 from the previous close of $21.46 during today's trading session.
- The primary catalyst was a negative market reaction to the company's first-quarter 2026 financial results and operational update released after market close on April 30.
- Trading volume surged above average levels, indicating heightened investor activity amid the selloff.
- Biotech sector peers showed modest declines, with the XBI ETF down about 1.5% and IBB off roughly 1.2%.
- Traders are watching progress on the ivonescimab Biologics License Application (BLA) with the FDA and upcoming clinical data presentations.
Opening Summary
Summit Therapeutics Inc. (SMMT), a biopharmaceutical company developing ivonescimab, a bispecific antibody targeting PD-1 and VEGF for non-small cell lung cancer and other indications, saw its stock tumble sharply today. Shares dropped 27.83% to $15.49 from the prior session's closing price of $21.46. The steep decline reflects investor disappointment following the release of Q1 2026 financial results after the bell on April 30.
Earnings Results
Summit Therapeutics disclosed its financial results and operational progress for the first quarter ended March 31, 2026, late on April 30. While the company continues to advance its lead candidate ivonescimab, including FDA acceptance of a BLA for use in combination with chemotherapy for EGFR-mutated NSCLC patients post-TKI therapy, the market focused on near-term financials. Investors appeared concerned about ongoing cash burn associated with expanded clinical investments, contributing to the heavy selling pressure today. No revenue was reported, consistent with the company's clinical-stage status.
Market Context and Trading Activity
Trading volume for SMMT exceeded average daily levels, with millions of shares changing hands as sellers dominated. The move diverged sharply from the broader biotech sector, where key ETFs like XBI and IBB posted milder losses. Technically, the stock breached key support levels around $20, accelerating the downside momentum and triggering stop-loss orders.
Trending AI Robots
Tickeron offers hundreds of AI trading bots covering thousands of tickers across various strategies, timeframes, and performance metrics. The Trending AI Robots page curates only the strongest performers under current market conditions, providing investors with vetted, data-driven tools for automated trading. These bots employ diverse approaches, from momentum and mean reversion to machine learning predictions, helping users navigate volatile sectors like biotech. Explore the page to discover top-ranked bots potentially suited for tracking stocks like SMMT amid earnings-driven swings.
What Comes Next for SMMT
Investors will monitor FDA milestones for the ivonescimab BLA, including potential approval timelines for NSCLC indications. Additional Phase III data presentations from studies like HARMONi at conferences such as ELCC 2026 could provide further catalysts. The next earnings report for Q2 2026 is anticipated later in the year. Ongoing collaborations, such as with GSK on combination trials, add to the pipeline outlook. Risks include regulatory delays, clinical trial outcomes, and persistent cash needs in a competitive biotech landscape.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
SMMT's RSI Indicator ascends from oversold territory
The RSI Oscillator for SMMT moved out of oversold territory on June 12, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In of the 29 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 25, 2026. You may want to consider a long position or call options on SMMT as a result. In of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for SMMT just turned positive on June 17, 2026. Looking at past instances where SMMT's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SMMT advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for SMMT moved below the 200-day moving average on June 24, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SMMT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
SMMT broke above its upper Bollinger Band on July 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SMMT entered a downward trend on June 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SMMT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SMMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.284) is normal, around the industry mean (21.001). P/E Ratio (26.355) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). SMMT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (368.009).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel medicines
Industry Biotechnology